Health Care • Biotechnology: Pharmaceutical Preparations
$10.54 ▼ -0.08
(-0.75%)
MKT CAP: $544.1M • VOL: 224.3K
52W L $5 52W H $12
PBYI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $228.4M | $230.5M | $235.6M |
| YoY Revenue Growth % | -0.9% | -2.2% | — |
| Gross Profit | $170.2M | $166.1M | — |
| Gross Margin % | 74.5% | 72.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $37.3M | $31.0M | $32.6M |
| Operating Margin % | 16.3% | 13.4% | 13.9% |
| Net Income (GAAP) | $31.1M | $30.3M | $21.6M |
| EBITDA (Normalized) | $37.4M | $31.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $41.8M | $38.9M | $27.0M |
| Capital Expenditures (CapEx) | $71.0K | $56.0K | — |
| Free Cash Flow (FCF) | $41.7M | $38.9M | $27.0M |
| FCF Margin % | 18.3% | 16.9% | 11.5% |
| Return on Invested Capital (ROIC %) | 29.3% | 54.8% | — |
| Cash & Short-Term Equivalents | $29.6M | $69.2M | — |
| Total Debt (Short + Long Term) | $0 | $21.7M | — |
| Total Stockholders' Equity | $130.3M | $92.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PBYI.